Lazzeri C, Bonizzoli M, Batacchi S, Cianchi G, Franci A, Socci F, Chiostri M, Peris A. Right ventricle dysfunction does not predict mortality in patients with SARS-CoV-2-related acute respiratory distress syndrome on extracorporeal membrane oxygenation support. World J Cardiol 2023; 15(4): 165-173 [PMID: 37124973 DOI: 10.4330/wjc.v15.i4.165]
Corresponding Author of This Article
Chiara Lazzeri, MD, Chief Physician, Senior Researcher, ICU and ECMO Center, Largo brambilla 3, Florence 50134, Italy. lazzeri.ch@gmail.com
Research Domain of This Article
Critical Care Medicine
Article-Type of This Article
Observational Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Cardiol. Apr 26, 2023; 15(4): 165-173 Published online Apr 26, 2023. doi: 10.4330/wjc.v15.i4.165
Right ventricle dysfunction does not predict mortality in patients with SARS-CoV-2-related acute respiratory distress syndrome on extracorporeal membrane oxygenation support
Chiara Lazzeri, Manuela Bonizzoli, Stefano Batacchi, Giovanni Cianchi, Andrea Franci, Filippo Socci, Marco Chiostri, Adriano Peris
Chiara Lazzeri, Manuela Bonizzoli, Stefano Batacchi, Giovanni Cianchi, Andrea Franci, Filippo Socci, Marco Chiostri, Adriano Peris, ICU and ECMO Center, Florence 50134, Italy
Author contributions: Lazzeri C was the guarantor and designed the study; Batacchi S, Cianchi G, Franci A and Socci F participated in the acquisition, analysis, and interpretation of data; Bonizzoli M, Chiostri M and Peris A drafted the initial manuscript; and all authors revised the article critically for important intellectual content.
Institutional review board statement: The study protocol was approved by our Ethical Committee (“Comitato Etico Area Vasta Centro” n.17024, approved on March 31th 2020) (“Florence COVID ICU Registry”).
Informed consent statement: Patient’s consent was waived.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: No data sharing.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Chiara Lazzeri, MD, Chief Physician, Senior Researcher, ICU and ECMO Center, Largo brambilla 3, Florence 50134, Italy. lazzeri.ch@gmail.com
Received: November 19, 2022 Peer-review started: November 19, 2022 First decision: December 13, 2022 Revised: December 15, 2022 Accepted: March 17, 2023 Article in press: March 17, 2023 Published online: April 26, 2023 Processing time: 151 Days and 16.4 Hours
ARTICLE HIGHLIGHTS
Research background
Echocardiography is recognized as a clinical tool in coronavirus disease (COVID)-related respiratory failure needing veno-venous extracorporeal membrane oxygenation (VV ECMO).
Research motivation
The assessment of the prognostic role of right ventricle dilatation and dysfunction (RVDD) in COVID-related respiratory failure refractory to standard treatment requesting ECMO.
Research objectives
In COVID-related respiratory failure on ECMO RVDD is a common finding and identifies a subset of patients characterized by a more severe disease (as indicated by higher sequential organ failure assessment values and need of renal replacement therapy) by a higher in-intensive care unit (ICU) mortality. RVDD (also when considered separately) did not result independently associated with in-ICU mortality in these patients.
Research methods
Observational single center study.
Research results
An echocardiographic examination was performed before ECMO implantation.
Research conclusions
In patients with COVID-related respiratory failure on ECMO support, RVDD is a common finding and identifies a subset of patients characterized by a more severe disease and by a higher in-ICU mortality. RVDD (also when considered separately) did not result independently associated with in-ICU mortality in these patients.
Research perspectives
Risk stratification in COVID-related refractory respiratory failure.
